Substrate-induced protein stabilization reveals a predominant contribution from mature proteins to peptides presented on MHC class I

Journal of Immunology

Volumn 191, Issue 11, 2013, Pages 5410-5419

  Colbert, Jeff D ^a   Farfán Arribas, Diego J ^a   Rock, Kenneth L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; FK 506 BINDING PROTEIN; GREEN FLUORESCENT PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TETRACYCLINE;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; HAMSTER; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; RIBOSOME;

EID: 84888353584     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300078     Document Type: Article

References (56)

1. Rock, K. L., and A. L. Goldberg. 1999. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17: 739-779.
2. Ciechanover, A. 1994. The ubiquitin-proteasome proteolytic pathway. Cell 79: 13-21.
3. Grant, E. P., M. T. Michalek, A. L. Goldberg, and K. L. Rock. 1995. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J. Immunol. 155: 3750-3758.
4. Esquivel, F., J. Yewdell, and J. Bennink. 1992. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J. Exp. Med. 175: 163-168.
5. Yewdell, J. W., L. C. Antón, and J. R. Bennink. 1996. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157: 1823-1826.
6. Goldberg, A. L. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899.
7. Schubert, U., L. C. Antón, J. Gibbs, C. C. Norbury, J. W. Yewdell, and J. R. Bennink. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404: 770-774.
8. Vabulas, R. M., and F. U. Hartl. 2005. Protein synthesis upon acute nutrient restriction relies on proteasome function. Science 310: 1960-1963.
9. Golovina, T. N., S. E. Morrison, and L. C. Eisenlohr. 2005. The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J. Immunol. 174: 2763-2769.
10. Reits, E. A., J. C. Vos, M. Grommé, and J. Neefjes. 2000. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404: 774-778.
11. Dolan, B. P., L. Li, C. A. Veltri, C. M. Ireland, J. R. Bennink, and J. W. Yewdell. 2011. Distinct pathways generate peptides from defective ribosomal products for CD8+ T cell immunosurveillance. J. Immunol. 186: 2065-2072.
12. Dolan, B. P., A. A. Sharma, J. S. Gibbs, T. J. Cunningham, J. R. Bennink, and J. W. Yewdell. 2012. MHC class I antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mRNA. Proc. Natl. Acad. Sci. USA 109: 7025-7030.
13. Qian, S.-B., E. Reits, J. Neefjes, J. M. Deslich, J. R. Bennink, and J. W. Yewdell. 2006. Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J. Immunol. 177: 227-233.
14. Tellam, J., M. H. Fogg, M. Rist, G. Connolly, D. Tscharke, N. Webb, L. Heslop, F. Wang, and R. Khanna. 2007. Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J. Exp. Med. 204: 525-532.
15. Apcher, S., C. Daskalogianni, F. Lejeune, B. Manoury, G. Imhoos, L. Heslop, and R. Fåhraeus. 2011. Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc. Natl. Acad. Sci. USA 108: 11572-11577.
16. Croft, N. P., S. A. Smith, Y. C. Wong, C. T. Tan, N. L. Dudek, I. E. A. Flesch, L. C. W. Lin, D. C. Tscharke, and A. W. Purcell. 2013. Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog. 9: e1003129.
17. Farfán-Arribas, D. J., L. J. Stern, and K. L. Rock. 2012. Using intein catalysis to probe the origin of major histocompatibility complex class I-presented peptides. Proc. Natl. Acad. Sci. USA 109: 16998-17003.
18. York, I. A., S.-C. Chang, T. Saric, J. A. Keys, J. M. Favreau, A. L. Goldberg, and K. L. Rock. 2002. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat. Immunol. 3: 1177-1184.
19. Banaszynski, L. A., L.-C. Chen, L. A. Maynard-Smith, A. G. L. Ooi, and T. J. Wandless. 2006. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126: 995-1004.
20. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
21. Kincaid, E. Z., J. W. Che, I. York, H. Escobar, E. Reyes-Vargas, J. C. Delgado, R. M. Welsh, M. L. Karow, A. J. Murphy, D. M. Valenzuela, et al. 2012. Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat. Immunol. 13: 129-135.
22. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785.
23. Maynard-Smith, L. A., L.-C. Chen, L. A. Banaszynski, A. G. L. Ooi, and T. J. Wandless. 2007. A directed approach for engineering conditional protein stability using biologically silent small molecules. J. Biol. Chem. 282: 24866-24872.
24. Pruett-Miller, S. M., D. W. Reading, S. N. Porter, and M. H. Porteus. 2009. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet. 5: e1000376.
25. Fiebiger, B. M., A. Moosmann, U. Behrends, and J. Mautner. 2012. Mature proteins derived from Epstein-Barr virus fail to feed into the MHC class I antigenic pool. Eur. J. Immunol. 42: 3167-3173.
26. Waldo, G. S., B. M. Standish, J. Berendzen, and T. C. Terwilliger. 1999. Rapid protein-folding assay using green fluorescent protein. Nat. Biotechnol. 17: 691-695.
27. Yoshida, H., T. Matsui, A. Yamamoto, T. Okada, and K. Mori. 2001. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107: 881-891.
28. Chang,W. Y. C., D. Clements, and S. R. Johnson. 2010. Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 299: L393-L400.
29. Wilmann, P. G., J. Battad, J. Petersen, M. C. J. Wilce, S. Dove, R. J. Devenish, M. Prescott, and J. Rossjohn. 2006. The 2.1A crystal structure of copGFP, a representative member of the copepod clade within the green fluorescent protein superfamily. J. Mol. Biol. 359: 890-900.
30. Schwanhäusser, B., D. Busse, N. Li, G. Dittmar, J. Schuchhardt, J. Wolf, W. Chen, and M. Selbach. 2011. Global quantification of mammalian gene expression control. Nature 473: 337-342.
31. Tscherne, J. S., and S. Pestka. 1975. Inhibition of protein synthesis in intact HeLa cells. Antimicrob. Agents Chemother. 8: 479-487.
32. Siegel, M. R., and H. D. Sisler. 1963. Inhibition of protein synthesis in vitro by cycloheximide. Nature 200: 675-676.
33. Yewdell, J. W. 2011. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. Trends Immunol. 32: 548-558.
34. Egeler, E. L., L. M. Urner, R. Rakhit, C. W. Liu, and T. J. Wandless. 2011. Ligand-switchable substrates for a ubiquitin-proteasome system. J. Biol. Chem. 286: 31328-31336.
35. Dolan, B. P., J. J. Knowlton, A. David, J. R. Bennink, and J. W. Yewdell. 2010. RNA polymerase II inhibitors dissociate antigenic peptide generation from normal viral protein synthesis: a role for nuclear translation in defective ribosomal product synthesis? J. Immunol. 185: 6728-6733.
36. Okada, C. Y., and M. Rechsteiner. 1982. Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell 29: 33-41.
37. Milner, E., E. Barnea, I. Beer, and A. Admon. 2006. The turnover kinetics of major histocompatibility complex peptides of human cancer cells. Mol. Cell. Proteomics 5: 357-365.
38. Goldberg, A. L., and A. C. St John. 1976. Intracellular protein degradation in mammalian and bacterial cells: Part 2. Annu. Rev. Biochem. 45: 747-803.
39. Amshoff, C., H. M. Jäck, and I. G. Haas. 1999. Cycloheximide, a new tool to dissect specific steps in ER-associated degradation of different substrates. Biol. Chem. 380: 669-677.
40. Gerlinger, U.-M., R. Gückel, M. Hoffmann, D. H. Wolf, and W. Hilt. 1997. Yeast cycloheximide-resistant crl mutants are proteasome mutants defective in protein degradation. Mol. Biol. Cell 8: 2487-2499.
41. Hanna, J., D. S. Leggett, and D. Finley. 2003. Ubiquitin depletion as a key mediator of toxicity by translational inhibitors. Mol. Cell. Biol. 23: 9251-9261.
42. Rock, K. L., S. Gamble, and L. Rothstein. 1990. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249: 918-921.
43. Donohue, K. B., J. M. Grant, E. F. Tewalt, D. C. Palmer, M. R. Theoret, N. P. Restifo, and C. C. Norbury. 2006. Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology 119: 63-73.
44. Roscoe, D. M., K. Ishikawa, and D. S. Lyles. 1991. Role of de novo protein synthesis in target cells recognized by cytotoxic T lymphocytes specific for vesicular stomatitis virus. J. Virol. 65: 6856-6861.
45. Huang, X.-L., Z. Fan, B. A. Colleton, R. Buchli, H. Li, W. H. Hildebrand, and C. R. Rinaldo, Jr. 2005. Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons. J. Virol. 79: 3052-3062.
46. Cardinaud, S., S. R. Starck, P. Chandra, and N. Shastri. 2010. The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS ONE 5: e8692.
47. Khan, S., R. de Giuli, G. Schmidtke, M. Bruns, M. Buchmeier, M. van den Broek, and M. Groettrup. 2001. Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J. Immunol. 167: 4801-4804.
48. Paludan, C., D. Schmid, M. Landthaler, M. Vockerodt, D. Kube, T. Tuschl, and C. Münz. 2005. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307: 593-596.
49. Lee, D. Y., and B. Sugden. 2008. The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy. Oncogene 27: 2833-2842.
50. Landais, E., X. Saulquin, M. Bonneville, and E. Houssaint. 2005. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen. J. Immunol. 175: 7939-7946.
51. Taylor, G. S., H. M. Long, T. A. Haigh, M. Larsen, J. Brooks, and A. B. Rickinson. 2006. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J. Immunol. 177: 3746-3756.
52. Devreotes, P. N., and D. M. Fambrough. 1975. Acetylcholine receptor turnover in membranes of developing muscle fibers. J. Cell Biol. 65: 335-358.
53. Bennett, M. C., J. F. Bishop, Y. Leng, P. B. Chock, T. N. Chase, and M. M. Mouradian. 1999. Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274: 33855-33858.
54. Claydon, A. J., M. D. Thom, J. L. Hurst, and R. J. Beynon. 2012. Protein turnover: measurement of proteome dynamics by whole animal metabolic labelling with stable isotope labelled amino acids. Proteomics 12: 1194-1206.
55. Villanueva, M. S., P. Fischer, K. Feen, and E. G. Pamer. 1994. Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity 1: 479-489.
56. Sykulev, Y., M. Joo, I. Vturina, T. J. Tsomides, and H. N. Eisen. 1996. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4: 565-571.